GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totalling 623,300 shares, a growth of 240.4% from the July 31st total of 183,100 shares. Approximately 11.9% of the shares of the company are sold short. Based on an average daily volume of 6,760,000 shares, the short-interest ratio is presently 0.1 days.
GeoVax Labs Price Performance
Shares of NASDAQ GOVX traded down $0.97 during trading on Wednesday, hitting $5.00. 4,935,894 shares of the company were exchanged, compared to its average volume of 2,722,628. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The firm’s fifty day moving average price is $3.25 and its 200 day moving average price is $2.35.
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The company had revenue of $0.30 million for the quarter. During the same quarter in the prior year, the firm earned ($3.30) EPS. Analysts forecast that GeoVax Labs will post -7.41 EPS for the current fiscal year.
Institutional Investors Weigh In On GeoVax Labs
Wall Street Analyst Weigh In
GOVX has been the topic of a number of research reports. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Monday, August 12th. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. Roth Mkm initiated coverage on GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Noble Financial increased their price target on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, August 19th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.67.
View Our Latest Stock Report on GOVX
GeoVax Labs Company Profile
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
Recommended Stories
- Five stocks we like better than GeoVax Labs
- What is the S&P/TSX Index?
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- Using the MarketBeat Stock Split Calculator
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- What is the Dogs of the Dow Strategy? Overview and Examples
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.